Cargando…
Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
Specific BRAFV600E inhibitors (BRAFi) are highly effective in the treatment of melanoma. However, acquired drug resistances invariably develop after the initial response. Therefore, the identification of new mechanisms of acquired resistance gives important clues towards the development of therapies...
Autores principales: | Lehraiki, Abdelali, Cerezo, Michael, Rouaud, Florian, Abbe, Patricia, Allegra, Marilyne, Kluza, Jerome, Marchetti, Philippe, Imbert, Veronique, Cheli, Yann, Bertolotto, Corine, Ballotti, Robert, Rocchi, Stéphane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860830/ https://www.ncbi.nlm.nih.gov/pubmed/27462428 http://dx.doi.org/10.1038/celldisc.2015.30 |
Ejemplares similares
-
CD271 is an imperfect marker for melanoma initiating cells
por: Cheli, Yann, et al.
Publicado: (2014) -
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
por: Ballotti, Robert, et al.
Publicado: (2020) -
Immune Checkpoints in Cancers: From Signaling to the Clinic
por: Pisibon, Céline, et al.
Publicado: (2021) -
E2F1 inhibition mediates cell death of metastatic melanoma
por: Rouaud, Florian, et al.
Publicado: (2018) -
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)